Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer
Phase 1
Recruiting
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06710990
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 273
- Registration Number
- NCT06688123
- Locations
- 🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
🇨🇳Shanghai Sixth People's Hospital, Shanghai, Shanghai, China
A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone
Phase 1
Recruiting
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT06689163
- Locations
- 🇨🇳
The First Affiliated Hospital Of Anhui Medical University, Hefei, Anhui, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients
Phase 3
Recruiting
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: Noiiglutide InjectionDrug: Noiiglutide Placebo
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 124
- Registration Number
- NCT06649773
- Locations
- 🇨🇳
Beijing Chaoyang Hospital Affiliated to Capital, Beijing, Beijing, China
Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations
Phase 2
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Drug: HRG2010(I)Drug: HRG2010(II)Drug: Sustained-release Carbidopa/Levodopa
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-09-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 61
- Registration Number
- NCT06614153
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations
Phase 3
Recruiting
- Conditions
- Parkinson's Disease
- Interventions
- Drug: Sustained-release Carbidopa/Levodopa; HRG2010 placeboDrug: HRG2010; Sustained-release Carbidopa/Levodopa administered placebo
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT06596876
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06598735
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
Phase 3
Recruiting
- Conditions
- Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
- Interventions
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 578
- Registration Number
- NCT06569056
- Locations
- 🇨🇳
Shanghai Huashan Hospital, Shanghai, Shanghai, China
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
Phase 1
Recruiting
- Conditions
- Prostate Cancer
- Interventions
- Drug: HRS-5041 tabletsDrug: SHR2554 tablets
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06568094
- Locations
- 🇨🇳
The Second Affiliated Hospital of Harbin Medical University, Ha'erbin, Heilongjiang, China
🇨🇳Shanghai Jiao Tong University School of Medicine, Renji Hospital, Shanghai, Shanghai, China
A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients
Phase 1
Recruiting
- Conditions
- Advanced Unresectable or Metastatic Breast Cancer
- Interventions
- Drug: HRS-6209 in Combination with HRS-1358Drug: HRS-6209 in Combination with FulvestrantDrug: HRS-6209 in Combination with LetrozoleDrug: HRS-6209 in Combination with HRS-8080
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 528
- Registration Number
- NCT06555068
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath